Menu
← Oncology Approval Tracker
FDA DECISION ·
Retevmo tablets
selpercatinib · Eli Lilly
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Tablet presentation for then-labeled RET-altered cancers, including adult RET fusion-positive locally advanced or metastatic non-small cell lung cancer, qualifying RET-altered medullary or other thyroid cancers from age 12, and qualifying adult RET fusion-positive solid tumors.
LAMPGEN ANALYSIS
Why it matters
The tablet approval added a different presentation of the RET inhibitor before subsequent 2024 pediatric expansions.
What research teams should watch
Check which dosage form and strengths are being used, and apply the label appropriate to the patient and decision date.
PRIMARY RECORDS